The Oncology Pharmacist
  • Home
  • Issues
    • 2023
      • March 2023 - Vol 16 No 2
      • January 2023 - Vol 16 No 1
    • 2022
      • November 2022 - Vol 15 No 6
      • September 2022 - Vol 15 No 5
      • July 2022 - Vol 15 No 4
      • May 2022 - Vol 15 No 3
      • March 2022 - Vol 15 No 2
      • January 2022 - Vol 15 No 1 – Online Only
    • 2021
      • November 2021 - Vol 14 No 7
      • October 2021 - Vol 14 No 6 | Biosimilars
      • September 2021 - Vol 14 No 5
      • July 2021 - Vol 14 No 4
      • May 2021 - Vol 14 No 3
      • March 2021 - Vol 14 No 2
      • January 2021 - Vol 14 No 1
    • Issue Archive
  • Special Issues
    • Supplements
      • ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
        • Checkmate 9LA
    • Guide to New FDA Approvals
      • 2019 Fourth Annual Guide
      • 2018 Third Annual Guide
      • 2017 Second Annual Guide
      • 2016 First Annual Guide
  • Categories
  • Conference Correspondent
    • ASCO 2021 Wrap-Up - Breast Cancer
  • Web Exclusives
    • Ovarian Cancer Overview
    • Interview with the Innovators
    • All Web Exclusives
    • Drug Updates
    • FDA Approvals, News & Updates
    • In the News
    • Press Releases
    • Media Library
      • Videos
      • Audiocasts
  • Quick Quiz
  • CE
  • About
    • About TOP
    • Advertise
    • Editorial Board
    • Contact Us
    • Resources
    • Author Guidelines
The Oncology Pharmacist

Harris S. Goodman, MD

Medical Director, Clinical Laboratory
Saint Francis Memorial Hospital
San Francisco, CA

Authored Items
Ensuring Consistent and Reliable Biomarker Testing
Harris S. Goodman, MD
Faculty Perspectives–Rationale for PD-L1 Expression as a Biomarker in Immuno-Oncology | Part 2 of a 4-Part Series
Biomarkers and the Cancer Care Team: Critical Partners in Personalized Medicine
Harris S. Goodman, MD
Faculty Perspectives: An Overview of Existing and Emerging Biomarkers in Oncology | Part 1 of a 4-Part Series
Biomarkers and the Cancer Care Team: Critical Partners in Personalized Medicine
Harris S. Goodman, MD
Faculty Perspectives - An Overview of Existing and Emerging Biomarkers in Oncology | Part 1 of a 4-Part Series
Last modified: June 19, 2018
Latest Issue
 
  • Privacy Policy
  • Terms of Use
  • Home
  • About
  • Subscribe
  • Advertise
  • Contact Us

© Amplity Health. All rights reserved.
1249 South River Road - Suite 202, Cranbury, NJ 08512

  • Home
  • Issues
    • 2023
      • March 2023 - Vol 16 No 2
      • January 2023 - Vol 16 No 1
    • 2022
      • November 2022 - Vol 15 No 6
      • September 2022 - Vol 15 No 5
      • July 2022 - Vol 15 No 4
      • May 2022 - Vol 15 No 3
      • March 2022 - Vol 15 No 2
      • January 2022 - Vol 15 No 1 – Online Only
    • 2021
      • November 2021 - Vol 14 No 7
      • October 2021 - Vol 14 No 6 | Biosimilars
      • September 2021 - Vol 14 No 5
      • July 2021 - Vol 14 No 4
      • May 2021 - Vol 14 No 3
      • March 2021 - Vol 14 No 2
      • January 2021 - Vol 14 No 1
    • Issue Archive
  • Special Issues
    • Supplements
      • ASK THE EXPERT: First-Line Treatment of Metastatic Non-small cell Lung Cancer
        • Checkmate 9LA
    • Guide to New FDA Approvals
      • 2019 Fourth Annual Guide
      • 2018 Third Annual Guide
      • 2017 Second Annual Guide
      • 2016 First Annual Guide
  • Categories
  • Conference Correspondent
    • ASCO 2021 Wrap-Up - Breast Cancer
  • Web Exclusives
    • Ovarian Cancer Overview
    • Interview with the Innovators
    • All Web Exclusives
    • Drug Updates
    • FDA Approvals, News & Updates
    • In the News
    • Press Releases
    • Media Library
      • Videos
      • Audiocasts
  • Quick Quiz
  • CE
  • About
    • About TOP
    • Advertise
    • Editorial Board
    • Contact Us
    • Resources
    • Author Guidelines
Sign Up Now!

To sign up for our newsletter or print publications, please enter your contact information below and click "Subscribe".

I'd like to receive: